Abstracts tagged "prognostic factors and psoriatic arthritis"

Abstract Number: 608 • 2017 ACR/ARHP Annual Meeting
Presence of Poor Prognostic Factors May Predict Response to Abatacept in Patients with Active Psoriatic Arthritis: Results from a Post Hoc Analysis from a Phase III Study
Philip J Mease¹, Iain B. McInnes², Vibeke Strand³, O FitzGerald⁴, H Ahmad⁵, A Johnsen⁵, J Ye⁵ and S Banerjee⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Glasgow, Glasgow, Great Britain, ³Stanford University, Palo Alto, CA, ⁴Department of Rheumatology, St Vincent’s University Hospital and University College Dublin, Dublin, Ireland, ⁵Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, significantly increased ACR20 response and had an overall beneficial effect on musculoskeletal symptoms in patients with active psoriatic…
Abstract Number: 1698 • 2016 ACR/ARHP Annual Meeting
Late Onset Psoriatic Arthritis in a Longitudinal Cohort: Disease Presentation, Activity over Time and Prognosis
Ari Polachek¹, Roa'a Al Johani², Suzanne Li¹, Vinod Chandran¹ and Dafna D Gladman³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) often develops between the 3rd to 5th decades of life. However, little is known about PsA activity and prognosis among patients…
Abstract Number: 1576 • 2014 ACR/ARHP Annual Meeting
Reversal of Damage in Psoriatic Arthritis
Amir Haddad¹, Ker-Ai Lee², Arane Thavaneswaran¹, Vinod Chandran¹, Richard J. Cook² and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose Psoriatic arthritis could lead to severe damage and disability. However, cases of improvement in joint damage over time have been reported in the literature.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].